Literature DB >> 15508512

Prevention of opportunistic infections in immunosuppressed patients in the tropical top end of the Northern Territory.

Joshua S Davis1, Bart J Currie, Dale A Fisher, Sarah E Huffam, Nicholas M Anstey, Richard N Price, Vicki L Krause, Nathan Zweck, Paul D Lawton, Paul L Snelling, Sid Selva-Nayagam.   

Abstract

The population of the Top End of the Northern Territory has a high incidence of several infections of particular significance in the immunosuppressed. The following protocol for evaluation and treatment of patients prior to immunosuppression was developed in order to reduce the incidence of serious opportunistic infections. The infections discussed are Strongyloides stercoralis, tuberculosis, scabies, chronic hepatitis B, melioidosis and other bacterial infections. We recommend that all patients planned to receive more than 0.5 mg/kg/day of prednisolone for >14 days, or any more potent immunosuppressive drug, be evaluated and treated according to this protocol. Details of the rationale, evidence base, and proposed investigations and therapy for such patients are discussed.

Entities:  

Mesh:

Year:  2003        PMID: 15508512

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  12 in total

Review 1.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Case Report: A Case of Recurrent Strongyloides stercoralis Colitis in a Patient with Multiple Myeloma.

Authors:  Keith Glenn; David A Lindholm; Gregory Meis; Luisa Watts; Nicholas Conger
Journal:  Am J Trop Med Hyg       Date:  2017-11       Impact factor: 2.345

3.  Rapid Progress toward Elimination of Strongyloidiasis in North Queensland, Tropical Australia, 2000-2018.

Authors:  Matthew Paltridge; Simon Smith; Aileen Traves; Robyn McDermott; Xin Fang; Chris Blake; Brad Milligan; Andrew D'Addona; Josh Hanson
Journal:  Am J Trop Med Hyg       Date:  2020-02       Impact factor: 2.345

4.  Risk factors for delayed diagnosis of scabies in hospitalized patients from long-term care facilities.

Authors:  Chorng-Jang Lay; Chun-Lung Wang; Hui-Ying Chuang; Ya-Lan Chen; Hsiang-Ling Chen; Shu-Juan Tsai; Chen-Chi Tsai
Journal:  J Clin Med Res       Date:  2011-04-04

Review 5.  Strongyloides stercoralis: systematic review of barriers to controlling strongyloidiasis for Australian indigenous communities.

Authors:  Adrian Miller; Michelle L Smith; Jenni A Judd; Rick Speare
Journal:  PLoS Negl Trop Dis       Date:  2014-09-25

6.  Strongyloides seroprevalence before and after an ivermectin mass drug administration in a remote Australian Aboriginal community.

Authors:  Therese M Kearns; Bart J Currie; Allen C Cheng; James McCarthy; Jonathan R Carapetis; Deborah C Holt; Wendy Page; Jennifer Shield; Roslyn Gundjirryirr; Eddie Mulholland; Linda Ward; Ross M Andrews
Journal:  PLoS Negl Trop Dis       Date:  2017-05-15

7.  Integrating testing for chronic strongyloidiasis within the Indigenous adult preventive health assessment system in endemic communities in the Northern Territory, Australia: An intervention study.

Authors:  Wendy A Page; Jenni A Judd; David J MacLaren; Petra Buettner
Journal:  PLoS Negl Trop Dis       Date:  2020-05-13

8.  Trimethoprim+Sulfamethoxazole Reduces Rates of Melioidosis in High-Risk Hemodialysis Patients.

Authors:  Sandawana William Majoni; Jaquelyne T Hughes; Bianca Heron; Bart J Currie
Journal:  Kidney Int Rep       Date:  2017-09-20

9.  Melioidosis in a patient with type 1 diabetes mellitus on an insulin pump.

Authors:  Melissa Katz; Simon Smith; Luke Conway; Ashim Sinha
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-07-31

Review 10.  Melioidosis: An Australian Perspective.

Authors:  Simon Smith; Josh Hanson; Bart J Currie
Journal:  Trop Med Infect Dis       Date:  2018-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.